HIGHOutside partySupplier
Unomedical A/S
“10-K Item 1: 'we purchase all of our currently marketed infusion sets from a third-party supplier, Unomedical A/S, a subsidiary of the ConvaTec Group'”
TNDM · Concentration risk · 10-K extracted
Tandem Diabetes Care (TNDM) concentration risks
Updated
The most significant concentration Tandem Diabetes Care discloses is Unomedical A/S, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Tandem Diabetes Care’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH1
MEDIUM0
LOW1
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
LOWOutside partyCustomer
two independent distributors >10%
“10-K Item 1: 'two independent distributors each accounted for more than 10% of our worldwide sales'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's disclosed concentration profile combines a high-share manufacturing dependency with a low-share customer distribution exposure. The dominant disclosed risk is the sole-source supplier relationship for infusion sets: the company purchases all of its currently marketed infusion sets from a single third-party supplier, Unomedical A/S, a subsidiary of the ConvaTec Group. This is a high-share dependency — the infusion set is a core physical component of the product offering, and the filing's use of "all" indicates there is no partial alternative sourcing in place. Any disruption at Unomedical A/S — whether from manufacturing quality issues, regulatory action, ConvaTec's corporate priorities, or a contractual dispute — would directly affect the company's ability to supply patients and recognize revenue. Qualifying an alternative supplier would typically require regulatory approval, extending the timeline for recovery. The customer distribution side carries a lower-share but still noted exposure: two independent distributors each accounted for more than 10% of worldwide sales — a low-share, dependency-character exposure indicating that the distribution channel has some concentration without a single dominant party. This is a secondary concern relative to the Unomedical dependency; losing one distributor relationship would be disruptive but is less operationally irreversible than a sole-source supplier failure. In aggregate, the Unomedical A/S relationship is the defining concentration risk in the profile: it is a single point of failure in the manufacturing supply chain for the company's primary product, and its management warrants close monitoring by investors focused on operational continuity.
For the engine’s reasoning on TNDM’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Devices
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AORT | Artivion, Inc. | 4 | 4 | 0 | 8 |
| ATEC | Alphatec Holdings, Inc. | 1 | 1 | 0 | 2 |
| TNDM● | Tandem Diabetes Care, Inc. | 1 | 0 | 1 | 2 |
| ABT | Abbott Laboratories | 1 | 0 | 0 | 1 |
| AXGN | AxoGen, Inc. | 0 | 0 | 0 | 0 |
| BIO | Bio-Rad Laboratories, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.